KR101060670B1 - Method for preparing ramipril - Google Patents

Method for preparing ramipril Download PDF

Info

Publication number
KR101060670B1
KR101060670B1 KR1020080064417A KR20080064417A KR101060670B1 KR 101060670 B1 KR101060670 B1 KR 101060670B1 KR 1020080064417 A KR1020080064417 A KR 1020080064417A KR 20080064417 A KR20080064417 A KR 20080064417A KR 101060670 B1 KR101060670 B1 KR 101060670B1
Authority
KR
South Korea
Prior art keywords
ramipril
benzyl group
reaction
octane
azabicyclo
Prior art date
Application number
KR1020080064417A
Other languages
Korean (ko)
Other versions
KR20100004315A (en
Inventor
구대호
백영찬
신용봉
Original Assignee
주식회사 하원제약
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 하원제약 filed Critical 주식회사 하원제약
Priority to KR1020080064417A priority Critical patent/KR101060670B1/en
Publication of KR20100004315A publication Critical patent/KR20100004315A/en
Application granted granted Critical
Publication of KR101060670B1 publication Critical patent/KR101060670B1/en

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

(S,S,S)-2-아자비사이클로(3,3,0)-옥탄-3-카르복실산 벤질 에스터로부터 벤질기를 분리한 후, 이를 N-[1(S)-에톡시카보닐-3-페닐프로필]-L-알라닌-N-카복시무수물과 반응시켜 라미프릴을 제조하는 방법이 개시된다. 이는, Pd/C(탄소 함유 팔라듐 촉매)와 수소가스를 사용하지 않으므로, 작업 안전성이 우수하고 반응 후 남는 금속물질의 폐기처리 문제를 발생시키지 않을 뿐만 아니라, 생산효율이 뛰어나다는 장점이 있다. After separating the benzyl group from (S, S, S) -2-azabicyclo (3,3,0) -octane-3-carboxylic acid benzyl ester, this was followed by N- [1 (S) -ethoxycarbonyl- A method for preparing ramipril by reacting with 3-phenylpropyl] -L-alanine-N-carboxy anhydride is disclosed. Since it does not use Pd / C (carbon-containing palladium catalyst) and hydrogen gas, it has advantages in that it is excellent in work safety and does not cause a problem of disposal of metal materials remaining after the reaction, and also has excellent production efficiency.

라미프릴, 강염기, 약염기, KOH, NaOH, TEA, 메틸 클로라이드 Ramipril, strong base, weak base, KOH, NaOH, TEA, methyl chloride

Description

라미프릴의 제조방법{Process for the Preparation of Ramipril}Process for the Preparation of Ramipril

본 발명은 라미프릴을 제조하는 방법에 관한 것이다. 더 상세하게는, Pd/C(탄소 함유 팔라듐 촉매)와 수소가스를 사용하지 않고, 라미프릴을 제조하는 방법에 관한 것이다. The present invention relates to a process for preparing ramipril. More specifically, the present invention relates to a method for producing ramipril without using Pd / C (carbon-containing palladium catalyst) and hydrogen gas.

라미프릴(Ramipril)은 안지오텐신 전환 효소(Angiotesin Converting Enzyme; 이하 “ACE”라 함) 엑제제로서, 심혈관 질환, 특히 고혈압의 치료에 많이 사용되며, 울혈성 심부전증에 대해서도 효과적이다. 고혈압과 관련하여, 라미프릴은 말초 동맥 저항성을 감소시켜 맥박의 보상적 증가 없이 혈압을 감소시키는 것으로 알려져 있다. 또한 급성 심근 경색에서 소생한 뒤 울혈성 신부전증의 임상적 징후를 보이는 환자의 사망률을 감소시키는 것으로 보고된다. 라미프릴은, 예를 들어, 심장, 신장 및 혈관과 같은 기관에서 장기 보호 효과를 갖는 것으로 알려져 있다.Ramipril is an angiotesin converting enzyme (hereinafter referred to as “ACE”) exemption and is widely used for the treatment of cardiovascular diseases, especially hypertension, and is effective in congestive heart failure. In connection with hypertension, ramipril is known to reduce peripheral arterial resistance, thereby reducing blood pressure without compensating increase in pulse rate. It has also been reported to reduce mortality in patients with clinical signs of congestive renal failure after resuscitation in acute myocardial infarction. Ramipril is known to have long-term protective effects in organs such as, for example, the heart, kidneys and blood vessels.

이러한 라미프릴을 제조하는 방법으로는, 예를 들어, PCT출원 제WO 2005-121084 A1호 등에 개시되어 있다. 상기 PCT 출원을 살펴보면, 하기 반응식 1의 과 정을 거처 라미프릴을 제조하게 된다. As a method of manufacturing such ramipril, it is disclosed, for example in PCT application WO 2005-121084 A1. Looking at the PCT application, through the process of Scheme 1 to produce a ramipril.

[반응식 1] Scheme 1

Figure 112008048174815-pat00001
Figure 112008048174815-pat00001

상기 반응식 1에서는, (S,S,S)-2-아자비사이클로(3,3,0)-옥탄-3-카르복실산 벤질 에스터 염산염과 N-[1(S)-에톡시카보닐-3-페닐프로필]-L-알라닌-N-카복시무수물을 출발물질로 하여 Pd/C(탄소 함유 팔라듐 촉매)와 수소가스를 첨가하여 라미프릴을 합성하게 된다. 구체적인 라미프릴 합성 과정은 하기 반응식 2와 같다. In Scheme 1, (S, S, S) -2-azabicyclo (3,3,0) -octane-3-carboxylic acid benzyl ester hydrochloride and N- [1 (S) -ethoxycarbonyl-3 Using -phenylpropyl] -L-alanine-N-carboxy anhydride as a starting material, ramipril is synthesized by adding Pd / C (carbon-containing palladium catalyst) and hydrogen gas. Specific ramipril synthesis process is shown in Scheme 2.

[반응식 2]Scheme 2

Figure 112008048174815-pat00002
Figure 112008048174815-pat00002

상기 반응식 2를 살펴보면, 금속 물질과 폭발성이 강한 수소가스를 사용하기 때문에 대량생산 과정에서 폭발의 위험성이 크다. 또한, 상기 반응식 2의 두 번째 단계에서는 Pd/c, 수소가스를 이용하여 벤질기를 제거하게 되는데, 이는 장치 설비비와 안전관리 유지비가 많이 들게 된다. 이 외에도, 기체를 사용하여 반응을 진행시키기 때문에, 반응시간이 길고 정량적인 반응을 이끌어내기가 어렵다. 특히, Pd/c 금속은 수분이 부족하면 불이 나거나 폭발 위험성이 있으며, 반응이 끝난 후 남는 Pd/c의 폐처리 문제도 많은 비용과 위험성을 수반하게 된다. Looking at the reaction scheme 2, since the use of a metallic material and a strong explosive hydrogen gas there is a high risk of explosion during mass production. In addition, in the second step of Scheme 2, benzyl groups are removed using Pd / c and hydrogen gas, which costs a lot of equipment equipment and safety management. In addition, since the reaction proceeds using a gas, the reaction time is long and it is difficult to elicit a quantitative reaction. In particular, the Pd / c metal is a fire or explosion risk when there is a lack of moisture, the waste treatment of Pd / c remaining after the reaction is accompanied with a lot of cost and risk.

따라서, 보다 안정적이고 위험성이 적으면서, 반응 시간을 절약할 수 있는 라미프릴 제조방법에 대한 필요성이 절실한 실정이다.Therefore, there is an urgent need for a method for preparing ramipril that can reduce reaction time while being more stable and less dangerous.

본 발명의 일실시예의 목적은 보다 안정적이고 효율적인 라미프릴의 제조방법을 제공하는 것이다. An object of one embodiment of the present invention is to provide a more stable and efficient method for preparing ramipril.

본 발명의 또 다른 일실시예의 목적은 반응 후 남는 금속물질(예, Pd/c)의 폐처리 문제를 발생시키지 않는 라미프릴의 제조방법을 제공하는 것이다.It is an object of another embodiment of the present invention to provide a method for preparing ramipril that does not cause a waste disposal problem of the metal material (eg, Pd / c) remaining after the reaction.

본 발명은 라미프릴의 제조방법에 관한 것으로, (i) (S,S,S)-2-아자비사이클로(3,3,0)-옥탄-3-카르복실산 벤질 에스터로부터 벤질기를 분리하는 단계; 및 (ii) 상기 벤질기가 분리된 (S,S,S)-2-아자비사이클로(3,3,0)-옥탄-3-카르복실산과 N-[1(S)-에톡시카보닐-3-페닐프로필]-L-알라닌-N-카복시무수물을 반응시켜 라미프릴을 합성하는 단계를 포함하는 것을 특징으로 하는 라미프릴의 제조방법을 제공한다. The present invention relates to a process for preparing ramipril, comprising: (i) separating a benzyl group from (S, S, S) -2-azabicyclo (3,3,0) -octane-3-carboxylic acid benzyl ester; And (ii) (S, S, S) -2-azabicyclo (3,3,0) -octane-3-carboxylic acid and N- [1 (S) -ethoxycarbonyl-3, wherein the benzyl group is separated. -Phenylpropyl] -L-alanine-N-carboxy anhydride provides a method for producing ramipril comprising the step of synthesizing ramipril.

본 발명에 따른 라미프릴 제조방법은, 폭발 위험성이 큰 수소가스를 사용하지 않기 때문에 작업 안전성이 우수하며, 반응 후 남는 금속물질의 폐기처리 문제를 발생시키지 않는다. 또한, 본 발명에 따른 라미프릴 제조방법은 저렴한 생산비용으로 대량생산이 가능하다는 장점이 있다. Since the ramipril manufacturing method according to the present invention does not use hydrogen gas having a high explosion risk, it is excellent in work safety and does not cause a problem of disposal of metal material remaining after the reaction. In addition, the ramipril manufacturing method according to the present invention has the advantage of being capable of mass production at a low production cost.

본 발명의 하나의 실시예에 따른 라미프릴 제조방법은, 하기 반응식 3과 같이 표현할 수 있다: Ramipril manufacturing method according to an embodiment of the present invention can be expressed as in Scheme 3:

[반응식 3]Scheme 3

Figure 112008048174815-pat00003
Figure 112008048174815-pat00003

상기 반응식 3에서는, (i) (S,S,S)-2-아자비사이클로(3,3,0)-옥탄-3-카르복실산 벤질 에스터로부터 벤질기를 제거하는 단계; 및 (ii) 상기 벤질기가 제거된 (S,S,S)-2-아자비사이클로(3,3,0)-옥탄-3-카르복실산과 N-[1(S)-에톡시카보닐-3-페닐프로필]-L-알라닌-N-카복시무수물을 반은시켜 라미프릴을 합성하는 단계를 포함하는 것을 특징으로 한다. In Scheme 3, (i) removing the benzyl group from (S, S, S) -2-azabicyclo (3,3,0) -octane-3-carboxylic acid benzyl ester; And (ii) (S, S, S) -2-azabicyclo (3,3,0) -octane-3-carboxylic acid and N- [1 (S) -ethoxycarbonyl-3 from which the benzyl group has been removed. -Phenylpropyl] -L-alanine-N-carboxy anhydride is characterized in that it comprises the step of synthesizing ramipril.

기존의 라미프릴 제조방법은, 상기 벤질기를 제거하기 위하여 Pd/c(탄소 함유 팔라듐) 촉매와 수소가스를 사용하게 된다. 그러나, 폭발의 위험성과 반응의 효율성 및 반응 후 남는 Pd/c의 폐처리 과정이 요구되는 종래의 방법과 비교하여, 금속 촉매와 수소가스를 사용하지 않기 때문에, 작업 안전성이 뛰어나고 반응 후 금속물질의 폐기처리 문제를 발생시키지 않는다는 장점이 있다. In the conventional ramipril production method, a Pd / c (carbon-containing palladium) catalyst and hydrogen gas are used to remove the benzyl group. However, in comparison with the conventional method requiring the risk of explosion, the efficiency of the reaction and the waste treatment of Pd / c remaining after the reaction, the metal catalyst and the hydrogen gas are not used, so the operation safety is excellent and the The advantage is that it does not cause disposal problems.

일실시예에서, 상기 (i) 단계는, (S,S,S)-2-아자비사이클로(3,3,0)-옥탄-3-카르복실산 벤질 에스터로부터 벤질기를 분리하기 위하여 강염기를 처리할 수 있다. 이는, 다른 작용기로부터 부반응이 일어나지 않도록 하기 위한 것이다. 상기 강염기는, 특별히 제한 되는 것은 아니나, KOH 또는 NaOH 등이 바람직하게 사용될 수 있다. In one embodiment, step (i) comprises the treatment of a strong base to separate the benzyl group from (S, S, S) -2-azabicyclo (3,3,0) -octane-3-carboxylic acid benzyl ester. can do. This is to avoid side reactions from other functional groups. The strong base is not particularly limited, but KOH or NaOH may be preferably used.

일실시예에서, 상기 (ii) 단계는, 상기 벤질기가 제거된 (S,S,S)-2-아자비사이클로(3,3,0)-옥탄-3-카르복실산과 N-[1(S)-에톡시카보닐-3-페닐프로필]-L-알라닌-N-카복시무수물를 약염기와 함께 혼합하여 반응시킬 수 있다. 상기 약염기는, 특별히 제한되는 것은 아니나, 바람직하게는 TEA(Triethylamine)일 수 있다. In one embodiment, the step (ii) is the (S, S, S) -2-azabicyclo (3,3,0) -octane-3-carboxylic acid and N- [1 (S) from which the benzyl group is removed. ) -Ethoxycarbonyl-3-phenylpropyl] -L-alanine-N-carboxy anhydride can be reacted by mixing with the weak base. The weak base is not particularly limited, but may be preferably TEA (Triethylamine).

하나의 실시예에서, 상기 강염기는 NaOH 이고, 상기 약염기는 TEA인 경우, 본 발명에 따른 라미프릴의 합성 과정은 하기 반응식 4과 같다. In one embodiment, when the strong base is NaOH, the weak base is TEA, the synthesis process of ramipril according to the present invention is shown in Scheme 4.

[반응식 4]Scheme 4

Figure 112008048174815-pat00004
Figure 112008048174815-pat00004

또 따른 일실시예에서, 상기 (i) 단계에서 제거된 벤질기를 분리한 후, 분리된 벤질기를 제거하는 별도의 과정 없이, (ii) 단계를 수행할 수 있다. 이는 (S,S,S)-2-아자비사이클로(3,3,0)-옥탄-3-카르복실산 벤질 에스터 염산염에서 벤질기를 분리한 후, 분리된 벤질기를 제거하고 반응을 진행하게 되면, 의도하지 않은 부반응이 일어날 우려가 있기 때문이다. 또한, 이후 설명하는 추출 및 정제 단계를 거치는 과정에서, 상기 분리된 벤질기를 제거하지 않고 반응을 진행시킨 경우에, 보다 안정적인 반응수율이 얻어진다는 장점이 있다. In another embodiment, after separating the benzyl group removed in step (i), without the separate process of removing the separated benzyl group, step (ii) can be carried out. When the benzyl group is separated from (S, S, S) -2-azabicyclo (3,3,0) -octane-3-carboxylic acid benzyl ester hydrochloride, the separated benzyl group is removed and the reaction proceeds. This is because unintended side reactions may occur. In addition, in the course of the extraction and purification steps to be described later, when the reaction proceeds without removing the separated benzyl group, there is an advantage that a more stable reaction yield is obtained.

또한, 본 발명에 따른 제조방법에 의해 합성된 라미프릴은, 다음의 후처리 단계를 통해 추출 또는 정제될 수 있다.In addition, ramipril synthesized by the production method according to the present invention can be extracted or purified through the following work-up step.

일실시예에서, 상기 라미프릴의 제조방법은, (iii) 상기 합성된 라미프릴을 메틸 클로라이드(metyl chloride)를 이용하여 추출하는 단계를 더 포함할 수 있다. 라미프릴이 포함된 반응용액에 대해, 메틸 클로라이드를 이용하여 추출하는 단계를 거치게 되면, 라미프릴의 생산 수율을 현저히 향상시키는 효과가 있다.In one embodiment, the method for preparing ramipril may further include (iii) extracting the synthesized ramipril using methyl chloride. For the reaction solution containing ramipril, the extraction step using methyl chloride has an effect of significantly improving the yield of ramipril.

또 다른 일실시예에서, 상기 라미프릴의 제조방법은, (iv) 상기 합성된 라미프릴을 메틸 클로라이드를 이용하여 추출한 후, 헵탄(heptan) 또는 헥산(hexan)을 이용하여 고체 결정을 얻는 단계를 더 포함할 수 있다. 이는, 반응 종료 후 헵탄 또는 헥산을 이용하여 고체의 결정을 얻어내지 않으면, 반응 수율이 저하될 우려가 있기 때문이다. 특히, 에틸 아세테이트, 메틸 클로라이트, 에탄올, 메탄올 등을 이용하면, 반응 수율이 저하될 뿐만 아니라, 결정화 반응의 진행이 저하되고, 부반응이 일어날 우려가 커지게 된다. In another embodiment, the method for preparing ramipril further includes the step of (iv) extracting the synthesized ramipril using methyl chloride, and then obtaining solid crystals using heptane or hexane. can do. This is because there is a fear that the reaction yield may be lowered unless a solid crystal is obtained using heptane or hexane after the completion of the reaction. In particular, when ethyl acetate, methyl chlorite, ethanol, methanol and the like are used, not only the reaction yield is lowered, but also the progress of the crystallization reaction is lowered, and there is a possibility that side reactions occur.

이하, 본 발명의 바람직한 실시예들을 통해 본 발명을 더욱 상술하지만, 하기 실시예들은 본 발명의 효과를 예시적으로 확인하기 위한 것이며, 본 발명의 범주가 이들만으로 한정되는 것은 아니다.Hereinafter, the present invention will be described in more detail with reference to preferred embodiments of the present invention, but the following examples are provided to clarify the effects of the present invention, and the scope of the present invention is not limited thereto.

[실시예 1] 라미프릴의 제조Example 1 Preparation of Ramipril

100 g의 (S,S,S)-2-아자비사이클로(3,3,0)-옥탄-3-카르복실산 벤질 에스터 염산염(0.4076 mol)을 500 ml Methanol에 녹였다. 상온에서, 상기 반응 용액에 150 ml의 4 N NaOH(45 g)를 30분 동안 적가한 다음, 24시간 교반하면서 가수분해 반응을 진행하였다. 24시간 후에, 기체크로마토그래피를 사용하여 닌히드린(Ninhydrin)으로 발색하여 벤질기의 분리를 확인하였다. 100 g of (S, S, S) -2-azabicyclo (3,3,0) -octane-3-carboxylic acid benzyl ester hydrochloride (0.4076 mol) was dissolved in 500 ml Methanol. At room temperature, 150 ml of 4 N NaOH (45 g) was added dropwise to the reaction solution for 30 minutes, followed by a hydrolysis reaction with stirring for 24 hours. After 24 hours, color separation with ninhydrin using gas chromatography confirmed separation of the benzyl group.

그런 다음, 상기 반응액을 pH 6으로 조절하여 중성화 한 후, 메탄올과 물을 완전히 제거하여 결정화하였다. 결정화된 물질에 대한 NMR을 측정한 결과, (S,S,S)-2-아자비사이클로(3,3,0)-옥탄-3-카르복실산 염산염임을 확인하였다. 또한, 상기 물질의 무게를 측정하여 반응 수율이 63%(63.3 g)임을 확인하였다. NMR 측정 결과는 도 1에 나타내었다.Then, the reaction solution was neutralized by adjusting the pH to 6, and then crystallized by completely removing methanol and water. The NMR of the crystallized material was determined to be (S, S, S) -2-azabicyclo (3,3,0) -octane-3-carboxylic acid hydrochloride. In addition, the weight of the material was measured to confirm that the reaction yield was 63% (63.3 g). The NMR measurement results are shown in FIG. 1.

1H NMR spectrum (300 MHz, CDCl3): δ 4.7(2.5H), 3.5(1H), 3.35(0.5H), 2.5(1H), 2.3 (1H), 1.8(1H), 1.6(3.5H), 1.4(1H), 1.3(0.5H) 1 H NMR spectrum (300 MHz, CDCl3): δ 4.7 (2.5H), 3.5 (1H), 3.35 (0.5H), 2.5 (1H), 2.3 (1H), 1.8 (1H), 1.6 (3.5H), 1.4 (1H), 1.3 (0.5H)

이를 다시 물 50 ml에 녹인 후, 아세토니트릴(Acetonnitril) 250 ml를 넣고 교반하였다. 30분 동안 교반한 후, 104 ml(2.5 eq)의 TEA를 30 분 동안 얼음 중탕에 적가하였다. 1당량의 N-[1(S)-에톡시카보닐-3-페닐프로필]-L-알라닌-N-카복시무수물 118 g(0.4078 mol)을 Acetonnitril 250ml에 녹인 후, (S,S,S)-2-아자비사이클로(3,3,0)-옥탄-3-카르복실산에 얼음중탕하여 1시간동안 적가하였다. 적가가 끝난 후, 20 내지 25℃에서 4시간 동안 교반하였다. 그런 다음, 기체크로마토그래피를 사용하여 반응 여부를 확인하였다. After dissolving it in 50 ml of water, 250 ml of acetonitrile was added and stirred. After stirring for 30 minutes, 104 ml (2.5 eq) of TEA was added dropwise to the ice bath for 30 minutes. One equivalent of N- [1 (S) -ethoxycarbonyl-3-phenylpropyl] -L-alanine-N-carboxy anhydride was dissolved in 250 ml of Acetonnitril after dissolving 118 g (0.4078 mol) of (S, S, S) To 2-azabicyclo (3,3,0) -octane-3-carboxylic acid was added dropwise for 1 hour in ice. After the dropwise addition, the mixture was stirred at 20 to 25 ° C. for 4 hours. Then, the reaction was confirmed using gas chromatography.

상기 반응액을 pH 4~5로 적정한 다음, 100 ml의 염화메틸(methyl chloride)로 3번 추출한 후, 이를 모아서 MgSO4를 이용하여 물을 완전히 제거하고 감압증류 하였다.The reaction solution was titrated to pH 4-5, extracted three times with 100 ml of methyl chloride, collected, and completely removed with MgSO 4 and distilled under reduced pressure.

감압증류 후 30 ml의 에틸 아세테이트(Ethyl acetate)로 용해하고, 이를 헵탄(heptan) 180 ml에 빠르게 적가한 후, 0℃ 이하에서 8 시간 동안 교반하였다. 교반 후, 고체 물질을 필터링하고, 150 ml의 에틸 아세테이트를 넣고 완전히 용해시켰다. 고체 물질이 용해된 반응액을 0℃ 이하에서 8시간 동안 냉각하여 흰 색의 고체 물질이 생성되는 것을 확인하였다. 상기 흰 색의 고체 물질을 여과한 후, 83℃에서 8시간 동안 건조하였다. After distillation under reduced pressure, the solution was dissolved in 30 ml of ethyl acetate, and rapidly added dropwise to 180 ml of heptane, followed by stirring at 0 ° C. or lower for 8 hours. After stirring, the solid material was filtered off, 150 ml of ethyl acetate was added and completely dissolved. The reaction solution in which the solid material was dissolved was cooled for 8 hours at 0 ° C. or less to confirm that a white solid material was produced. The white solid material was filtered off and dried at 83 ° C. for 8 hours.

건조된 물질에 대한 NMR을 측정한 결과, 라미프릴임을 확인하였다. 또한, 상기 과정을 거쳐 제조된 라미프릴은 순도 99.8% 이상이며, 126.9 g(수율: 70%)이었다. 라미프릴에 대한 NMR 측정 결과는 도 2에 나타내었다.NMR of the dried material was measured and found to be ramipril. In addition, the ramipril prepared through the above process was at least 99.8% pure and 126.9 g (yield: 70%). The NMR measurement results for ramipril are shown in FIG. 2.

1H NMR spectrum (300 MHz, CDCl3): δ 7.29-7.15 m (5H), 5.8 bs (2H), 4.62 dd (5.6 Hz, 9.4Hz) (0.5H), 4.43 m (0.2H), 4.21-4.1 m (3.5H), 3.72 q(6.6Hz) (0.5H), 3.18 t (6.7Hz) (0.5H), 2.80-1.40 m (12H), 1.39 d (6.9Hz) 1.37 d (6.6Hz) (2H), 1.30 t (7.1Hz) 1.28 t (7.1Hz) 1.26 d (6.0Hz) 1.22 t (7.1Hz) (4H) 1 H NMR spectrum (300 MHz, CDCl3): δ 7.29-7.15 m (5H), 5.8 bs (2H), 4.62 dd (5.6 Hz, 9.4 Hz) (0.5H), 4.43 m (0.2H), 4.21-4.1 m (3.5H), 3.72 q (6.6 Hz) (0.5H), 3.18 t (6.7 Hz) (0.5H), 2.80-1.40 m (12H), 1.39 d (6.9 Hz) 1.37 d (6.6 Hz) (2H ), 1.30 t (7.1 Hz) 1.28 t (7.1 Hz) 1.26 d (6.0 Hz) 1.22 t (7.1 Hz) (4H)

[실시예 2] 라미프릴의 제조Example 2 Preparation of Ramipril

100 g의 (S,S,S)-2-아자비사이클로(3,3,0)-옥탄-3-카르복실산 벤질 에스터 염산염(0.4076 mol)을 500 ml의 톨루엔에 넣고 교반한 후, 10~15℃에서 200 ml의 4 N NaOH를 적가하였다. 적가가 끝난 후, 실온에서 24시간 교반하면서 가수분해 반응을 실시하였다. 24시간 후에, 기체크로마토그래피를 사용하여 닌히드린으로 발색하여 벤질기의 제거를 확인하였다. 100 g of (S, S, S) -2-azabicyclo (3,3,0) -octane-3-carboxylic acid benzyl ester hydrochloride (0.4076 mol) was added to 500 ml of toluene, followed by stirring. 200 ml of 4 N NaOH was added dropwise at 15 ° C. After completion of the dropwise addition, the hydrolysis reaction was carried out while stirring at room temperature for 24 hours. After 24 hours, the development of benzyl group was confirmed by color development with ninhydrin using gas chromatography.

그런 다음, 상기 반응 용액에 염산(HCl)을 적가하여 pH 3~4로 산성화 한 후, 물층에 아세톤(Aceton) 250 ml를 넣어 교반하였다. 30분 동안 교반한 후, 104 ml(2.5 eq)의 TEA를 30분 동안 얼음 중탕에 적가하였다. 그리고 1당량의 N-[1(S)-에톡시카보닐-3-페닐프로필]-L-알라닌-N-카복시무수물 118 g(0.4078 mol)을 아세톤 250 ml에 녹인 후 (S,S,S)-2-아자비사이클로(3,3,0)-옥탄-3-카르복실산에 얼음 중탕하여 1시간 동안 적가하였다. 적가가 끝난 후, 상기 반응 용액을 20~25℃에서 4시간 동안 교반하였다. 반응이 결과 여부는 기체크로마토그래피를 사용하여 확인하였다. Then, hydrochloric acid (HCl) was added dropwise to the reaction solution and acidified to pH 3-4, and 250 ml of acetone was added to the water layer and stirred. After stirring for 30 minutes, 104 ml (2.5 eq) of TEA was added dropwise to the ice bath for 30 minutes. And 1 equivalent of 118 g (0.4078 mol) of N- [1 (S) -ethoxycarbonyl-3-phenylpropyl] -L-alanine-N-carboxy anhydride was dissolved in 250 ml of acetone (S, S, S ) Was added dropwise over 1 hour with ice-bathing to azazacyclo (3,3,0) -octane-3-carboxylic acid. After the dropwise addition, the reaction solution was stirred at 20-25 ° C. for 4 hours. Whether the reaction was the result was confirmed using gas chromatography.

그런 다음, 반응물에 남는 고체를 필터링 한 후, 용매 pH를 4~5로 산성화하고, 아세톤을 모두 제거한 후 물층을 염화메틸로 추출하여 농축하였다. 농축된 물질을 30 ml의 에틸 아세테이트로 용해 한 후, 헵탄(heptan) 180 ml에 0oC 이하에서 적가하였다. 상기 반응 용액에서 고체를 여과하고, 유기용매를 완전히 제거하였다. 83℃에서 건조한 후, 건조된 물질을 디에틸 아세테이트로 재결정화하였다. 반응 결과, 약 60% 순도, 100.38 g의 라미프릴을 얻을 수 있었다. Then, after filtering the solid remaining in the reaction, the solvent pH was acidified to 4-5, after removing all acetone, the water layer was extracted with methyl chloride and concentrated. The concentrated material was dissolved in 30 ml of ethyl acetate and then added dropwise to 180 ml of heptane at 0 ° C. or lower. Solids were filtered out of the reaction solution, and the organic solvent was completely removed. After drying at 83 ° C., the dried material was recrystallized from diethyl acetate. As a result, about 60% purity and 100.38 g of ramipril were obtained.

[실시예 3] 라미프릴의 제조Example 3 Preparation of Ramipril

100g의 (S,S,S)-2-아자비사이클로(3,3,0)-옥탄-3-카르복실산 벤질 에스터 염산염(0.4076 mol)을 500 ml 에탄올에 녹인 후, 실온에서 150 ml의 4 N KOH를 30분 동안 적가한 다음, 24시간 교반하면서 가수분해 반응을 진행하였다. 24시간 후에, 기체크로마토그래피를 사용하여 닌히드린(Ninhydrin)으로 발색하여 벤질기의 분리를 확인하였다. 100 g of (S, S, S) -2-azabicyclo (3,3,0) -octane-3-carboxylic acid benzyl ester hydrochloride (0.4076 mol) was dissolved in 500 ml ethanol and then 150 ml of 4 at room temperature. N KOH was added dropwise for 30 minutes, followed by a hydrolysis reaction with stirring for 24 hours. After 24 hours, color separation with ninhydrin using gas chromatography confirmed separation of the benzyl group.

이 후, pH를 6으로 중성화하고, 에탄올과 물을 완전히 제거하여 결정화한 다음 무게를 측정하였다. 측정결과, 63%(63.3 g)의 수율을 나타낸다는 것을 확인하였다. Thereafter, the pH was neutralized to 6, crystallized by completely removing ethanol and water and weighed. As a result, it was confirmed that the yield was 63% (63.3 g).

이를 다시 물 50 ml에 녹인 후, 아세톤 250 ml를 넣고 교반하였다. 30분 동안 교반 후, 104 ml(2.5eq)의 TEA를 30분 동안 얼음 중탕에 적가하고, 1당량의 N-[1(S)-에톡시카보닐-3-페닐프로필]-L-알라닌-N-카복시무수물 118 g(0.4078 mol)을 아세토니트릴 250 ml에 녹인 후, (S,S,S)-2-아자비사이클로(3,3,0)-옥탄-3-카르복실산에 얼음중탕하여 1시간동안 적가하였다. 적가가 끝난 후, 20~25℃℃에서 4시간 동안 교반하였다. 반응의 결과 여부는 기체크로마토그래피를 사용하여 판단하였다.After dissolving it in 50 ml of water, 250 ml of acetone was added thereto and stirred. After stirring for 30 minutes, 104 ml (2.5eq) of TEA was added dropwise to the ice bath for 30 minutes and 1 equivalent of N- [1 (S) -ethoxycarbonyl-3-phenylpropyl] -L-alanine- 118 g (0.4078 mol) of N-carboxy anhydride was dissolved in 250 ml of acetonitrile, and then ice-cold in (S, S, S) -2-azabicyclo (3,3,0) -octane-3-carboxylic acid. It was added dropwise for 1 hour. After the dropwise addition, the mixture was stirred at 20-25 ° C. for 4 hours. The result of the reaction was judged using gas chromatography.

이 후, 반응액을 pH를 4~5로 적정한 후, 100 ml의 메틸 클로라이드 로 3 번 추출하고, 추출된 물질을 MgSo4를 이용하여 물을 완전히 제거 후, 감압증류 하였다.Thereafter, the reaction solution was titrated to 4-5, extracted three times with 100 ml of methyl chloride, and the extracted material was completely removed using MgSo 4, and then distilled under reduced pressure.

감압증류 후 30 ml의 에틸 아세테이트(Ethyl acetate)로 용해하고, 이를 헵탄(heptan) 180 ml에 빠르게 적가한 후, 0℃ 이하에서 8 시간 동안 교반하였다. 교반 후, 고체 물질을 필터링하고, 150 ml의 에틸 아세테이트를 넣고 완전히 용해시켰다. 고체 물질이 용해된 반응액을 0℃ 이하에서 8시간 동안 냉각하여 흰 색의 고체 물질이 생성되는 것을 확인하였다. 상기 흰 색의 고체 물질을 여과한 후, 83℃에서 8시간 동안 건조하였다. 상기 과정을 거쳐 제조된 라미프릴은 순도 99.8% 이상이며, 126.9 g(수율: 70%)이었다.After distillation under reduced pressure, the solution was dissolved in 30 ml of ethyl acetate, and rapidly added dropwise to 180 ml of heptane, followed by stirring at 0 ° C. or lower for 8 hours. After stirring, the solid material was filtered off, 150 ml of ethyl acetate was added and completely dissolved. The reaction solution in which the solid material was dissolved was cooled for 8 hours at 0 ° C. or less to confirm that a white solid material was produced. The white solid material was filtered off and dried at 83 ° C. for 8 hours. Ramipril prepared through the above process was more than 99.8% purity, 126.9 g (yield: 70%).

도 1은, 본 발명의 일실시예에 따른 라미프릴의 제조과정 중, 벤질 에스터를 제거한 중간체인 (S,S,S)-2-아자비사이클로(3,3,0)-옥탄-3-카르복실산 염산염에 대한 NMR 측정결과이다. 1 is (S, S, S) -2-azabicyclo (3,3,0) -octane-3-carboxyl, an intermediate in which benzyl ester is removed during the preparation of ramipril according to an embodiment of the present invention. NMR measurement results for acid hydrochloride.

도 2는 본 발명의 일실시예에 따라 제조된 라미프릴에 대한 NMR 측정결과이다. 2 is an NMR measurement result for ramipril prepared according to an embodiment of the present invention.

Claims (8)

라미프릴의 제조방법에 있어서,In the method for producing ramipril, (i) (S,S,S)-2-아자비사이클로(3,3,0)-옥탄-3-카르복실산 벤질 에스터에 KOH 또는 NaOH를 처리하여 벤질기를 분리하는 단계; 및(i) treating the (S, S, S) -2-azabicyclo (3,3,0) -octane-3-carboxylic acid benzyl ester with KOH or NaOH to separate the benzyl group; And (ii) 상기 벤질기가 분리된 (S,S,S)-2-아자비사이클로(3,3,0)-옥탄-3-카르복실산과 N-[1(S)-에톡시카보닐-3-페닐프로필]-L-알라닌-N-카복시무수물을 트리에틸아민(triethylamine, TEA)와 함께 혼합하여 반응시켜 라미프릴을 합성하는 단계를 포함하는 것을 특징으로 하는 라미프릴의 제조방법.(ii) (S, S, S) -2-azabicyclo (3,3,0) -octane-3-carboxylic acid and N- [1 (S) -ethoxycarbonyl-3-, wherein the benzyl group was separated A phenylpropyl] -L-alanine-N-carboxy anhydride is mixed with triethylamine (triethylamine, TEA) to react to produce a ramipril comprising the step of synthesizing ramipril. 삭제delete 삭제delete 삭제delete 삭제delete 제 1 항에 있어서,The method of claim 1, 상기 (i) 단계에서 벤질기를 분리한 후, 분리된 벤질기를 제거하는 별도의 과정 없이, (ii) 단계를 수행하는 것을 특징으로 하는 라미프릴의 제조방법.After separating the benzyl group in the step (i), without the separate process of removing the separated benzyl group, (ii) a method for producing a ramipril characterized in that the step is carried out. 제 1 항에 있어서,The method of claim 1, (iii) 상기 합성된 라미프릴을 메틸 클로라이드(metyl chloride)를 이용하여 추출하는 단계를 더 포함하는 것을 특징으로 하는 라미프릴의 제조방법.(iii) extracting the synthesized ramipril using methyl chloride (metyl chloride). 제 7 항에 있어서,The method of claim 7, wherein (iv) 상기 합성된 라미프릴을 메틸 클로라이드를 이용하여 추출한 후, 헵탄(heptan) 또는 헥산(hexan)을 이용하여 고체 결정을 얻는 단계를 더 포함하는 것을 특징으로 하는 라미프릴의 제조방법.(iv) extracting the synthesized ramipril using methyl chloride, and then obtaining solid crystals using heptane (heptan) or hexane (hexan).
KR1020080064417A 2008-07-03 2008-07-03 Method for preparing ramipril KR101060670B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020080064417A KR101060670B1 (en) 2008-07-03 2008-07-03 Method for preparing ramipril

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020080064417A KR101060670B1 (en) 2008-07-03 2008-07-03 Method for preparing ramipril

Publications (2)

Publication Number Publication Date
KR20100004315A KR20100004315A (en) 2010-01-13
KR101060670B1 true KR101060670B1 (en) 2011-09-01

Family

ID=41813898

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020080064417A KR101060670B1 (en) 2008-07-03 2008-07-03 Method for preparing ramipril

Country Status (1)

Country Link
KR (1) KR101060670B1 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6407262B1 (en) 2001-11-21 2002-06-18 Brantford Chemicals Inc. Process for the preparation of Ramipril

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6407262B1 (en) 2001-11-21 2002-06-18 Brantford Chemicals Inc. Process for the preparation of Ramipril

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
보건의료기술진흥사업 최종보고서 '고혈압 치료제 라미프릴의 안정성이 개선된 약학조성물 및 제조방법' (과제번호 A050444), (주)하원제약 (2006.05.12.) 사본 1부.*

Also Published As

Publication number Publication date
KR20100004315A (en) 2010-01-13

Similar Documents

Publication Publication Date Title
US9783506B2 (en) Process for the large scale production of 1H-[1,2,3]triazole and its intermediate 1-benzyl-1H-[1,2,3]triazole
US7279595B2 (en) Process for the preparation of high purity perindopril
US8367847B2 (en) Production of monatin enantiomers
SK282865B6 (en) Method of making (S)-3-(aminomethyl)-5-methylhexanoic acid
EP2590943B1 (en) Process and intermediates for preparation of an active ingredient
MX2008014759A (en) Synthesis of (s)-(+)-3-(aminomethyl)-5-methyl hexanoic acid.
US9771317B2 (en) Process for preparing lacosamide and related compounds
EP1367061B1 (en) Method for synthesis of perindopril and its pharmaceutically acceptable salts
KR101060670B1 (en) Method for preparing ramipril
CN107674016B (en) Preparation method of telaprevir intermediate and intermediate thereof
CN112479967B (en) Biliverdin compound, and preparation method and application thereof
WO2009098251A1 (en) NOVEL CYCLOALKANONE β-SUBSTITUTED ALANINE DERIVATIVES
RU2709493C1 (en) Method of producing roxadustat
CN112174798B (en) Synthesis method of Sakuba/valsartan sodium LCZ696
WO2012062109A1 (en) Methods for preparation of pharmaceutical intermediates of aliskiren
EP1732899B1 (en) Process for preparing cyclohexanediacetic acid monoamide
KR100696187B1 (en) Preparation method of 2-2-aminoethyl-1-methylpyrrolidine
CA2533005C (en) Novel method for the synthesis of perindopril and the pharmaceutically acceptable salts thereof
JP5230609B2 (en) Novel pharmaceutical intermediates and their use in the synthesis of ACE inhibitors
EP1987828A1 (en) salts of perindopril and their use in the therapy of hypertension
JP2512958B2 (en) 1-biphenylylethanol derivative and process for producing the same
JP2003137835A (en) Method for producing (r)-3-hydroxy-3-(2-phenyl)hexanoic acid
KR101014890B1 (en) Novel cyclic compounds and process for preparing them
KR20030025394A (en) Preparing Method for N-[3-{3-(1-Piperidinylmethyl)phenoxy}propyl]acetoxyacetamide
JP2004210660A (en) METHOD FOR PRODUCING BENZYL (2S,3aR,7aS)-1-{(S)-N-[(S)-1-ETHOXYCARBONYL-3-PHENYLPROPYL]ALANYL}HEXAHYDRO-2-INDOLINECARBOXYLATE

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20140822

Year of fee payment: 4

FPAY Annual fee payment

Payment date: 20150824

Year of fee payment: 5

FPAY Annual fee payment

Payment date: 20160621

Year of fee payment: 6

FPAY Annual fee payment

Payment date: 20170821

Year of fee payment: 7